CNC

CNC

USD

Centene Corporation Common Stock

$60.160+0.330 (0.552%)

Reaalajas hind

Healthcare
Healthcare Plans
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$59.830

Kõrge

$60.450

Madal

$59.060

Maht

0.75M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

29.9B

Tööstusharu

Healthcare Plans

Riik

United States

Kauplemisstatistika

Keskmine maht

4.98M

Börs

NYQ

Valuuta

USD

52 nädala vahemik

Madal $55.03Praegune $60.160Kõrge $80.59

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 2. mai 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

CNC: Centene Corporation Common Stock - What's Happening and What to Watch

Stock Symbol: CNC Generate Date: 2025-05-02 20:55:31

Alright, let's break down what's been going on with Centene (CNC) based on the latest news and price action. Think of this as getting the lowdown on the company and its stock.

Recent News Buzz: A Mixed Bag

So, what's the general feeling from the recent news about Centene? It's a bit of a mixed bag, honestly.

On one hand, you've got some good stuff happening operationally. They're rolling out new benefits for members in Oklahoma, which sounds positive for their business there. There's news about partnerships aimed at improving patient care, like the one involving Health Net (a Centene company) in Sacramento. Health Net also gave a big grant to add doctors in Los Angeles and committed funds to help rebuild after a fire. Plus, a Centene subsidiary won a Medicaid contract in Nevada. All these things point to the company actively working and securing business.

But then, you see a few different analysts – folks who cover the stock professionally – trimming their price targets. Jefferies lowered theirs from $64 to $61, Barclays from $93 to $84 (though they still rate it 'Overweight', meaning they think it could go up), and Baird from $71 to $69. Guggenheim just kept their 'Neutral' rating. Lowering price targets usually means these analysts see a bit less potential upside than they did before. There was also news about potential changes to Medicare drug price talks proposed by Trump, which is an external factor that could affect healthcare plans like Centene down the road.

Putting it together, you have some solid company-specific wins mixed with analysts being a bit less optimistic on the price front and some potential regulatory clouds.

Price Check: Choppy Waters Lately

Now, let's look at what the stock price itself has been doing lately. If you check the chart over the last month or two, it's been a bit of a rollercoaster. It started February around $63-$64, dipped, then recovered. It shot up quite a bit in early April, even hitting the mid-$60s for a moment. But since then, it's pulled back.

Right now, it's trading around $60.16 (based on the last price provided). It's been bouncing around in a range, especially after their first-quarter results came out a week or so ago (April 25th), which coincided with a noticeable drop in price that day. The recent movement has been a bit choppy, staying mostly between the high $50s and low $60s.

Looking ahead, the AI prediction model suggests a slight drift lower in the very near term – predicting small percentage drops for today and the next couple of days.

Outlook & Ideas: Proceed with Caution?

Okay, so putting the news buzz (mixed, analyst caution), the stock's recent moves (choppy, pulled back from April highs), and what the AI model is predicting (slight near-term dip) all together, what does it seem to suggest for the near term?

Well, with analysts lowering their price targets and the AI forecasting a slight dip over the next couple of days, the picture looks a bit cautious right now. It doesn't exactly scream "all clear ahead."

If you were thinking about getting involved with this stock, the data doesn't make a strong case for jumping in right this second. The AI prediction data actually points to a support level around $57.41 – that's a spot where the price might find some footing if it keeps drifting lower. It's something to potentially watch if you're patient and interested in a potential entry point if the price drops further.

For managing risk if you already hold shares or decide to buy, the AI data also suggested a stop-loss level around $56.75. That's a point below recent lows where you might consider cutting losses if the price keeps falling significantly. And for taking some profit if it bumps up slightly, $60.60 was mentioned as a potential target, which is pretty close to where it is now.

Company Context: Healthcare Plans

Just to quickly put this in perspective, remember that Centene is a big healthcare company. They primarily provide health plans, especially through government programs like Medicaid and Medicare, but also commercial plans. They have a lot of employees (over 60,000). This means news about government healthcare policy (like the Medicare drug talks) and their ability to win state contracts (like the Nevada Medicaid one) are really important drivers for their business and, in turn, their stock price.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always do your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Seotud uudised

PR Newswire

CENTENE SUBSIDIARY ARIZONA COMPLETE HEALTH JOINS SETTLEMENT AGREEMENT TO MOVE FORWARD WITH STATEWIDE LONG-TERM CARE MEDICAID CONTRACT

Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that its...

Vaata rohkem
CENTENE SUBSIDIARY ARIZONA COMPLETE HEALTH JOINS SETTLEMENT AGREEMENT TO MOVE FORWARD WITH STATEWIDE LONG-TERM CARE MEDICAID CONTRACT
PR Newswire

Oklahoma Complete Health Offers New and Upgraded Benefits for SoonerSelect Members in 2025

Oklahoma Complete Health introduces new and upgraded SoonerSelect benefits to support members. Enhancements to the value-added services aim to...

Vaata rohkem
Oklahoma Complete Health Offers New and Upgraded Benefits for SoonerSelect Members in 2025
Analyst Upgrades

Jefferies Maintains Hold on Centene, Lowers Price Target to $61

Jefferies analyst David Windley maintains Centene with a Hold and lowers the price target from $64 to $61.

Vaata rohkem
Jefferies Maintains Hold on Centene, Lowers Price Target to $61
Analyst Upgrades

Guggenheim Reiterates Neutral on Centeneto Neutral

Guggenheim analyst Jason Cassorla reiterates Centene from Neutral to Neutral.

Vaata rohkem
Guggenheim Reiterates Neutral on Centeneto Neutral
Analyst Upgrades

Barclays Maintains Overweight on Centene, Lowers Price Target to $84

Barclays analyst Andrew Mok maintains Centene with a Overweight and lowers the price target from $93 to $84.

Vaata rohkem
Barclays Maintains Overweight on Centene, Lowers Price Target to $84
PR Newswire

CENTENE CORPORATION REPORTS FIRST QUARTER 2025 RESULTS

Centene Corporation (NYSE: CNC) (the Company) announced today its financial results for the first quarter ended March 31, 2025. In summary, the 2025...

PR Newswire

Health Net, Dignity Health and Vivant Health Partner to Improve Patient Care in Sacramento Hospitals

A groundbreaking collaboration between Health Net (a Centene Corporation company), Dignity Health (a CommonSpirit Health member) and Vivant Health...

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Langev

Uuendatud kell: 3. mai 2025, 13:15

LangevNeutraalneTõusev

64.5% Kindlus

Risk ja kauplemine

Riskitase1/5
Madal risk
Sobib
VäärtusKonservatiivne
Kauplemisjuhend

Sisenemispunkt

$59.75

Võta kasum

$61.33

Peata kahjum

$57.54

Põhitegurid

PDI 6.2 is above MDI 4.1 with ADX 16.2, suggesting bullish trend
Praegune hind on tugitasemele ($59.93) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 10.2x keskmisest (47,802), mis viitab äärmiselt tugevale ostusurvele
MACD 0.0621 on signaalijoone 0.0560 kohal, mis viitab tõusvale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.